PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP
INTERNAL MEMORANDUM
February 12, 2026
To: Stephanie Okafor, Partner, Banking & Finance
From: Sophie Tremblay, Lead Associate, Banking & Finance Daniel Obi, Working Associate, Banking & Finance
Reviewed by: Ian Blackwood, Responsible Partner, Banking & Finance
Re: Genome Dx Therapeutics Inc. — Proposed $15,000,000 Senior Secured Bridge Loan — Deal Summary and Key Issues
Matter No.: 14892.003
This memorandum is confidential attorney work product prepared in connection with our representation of Genome Dx Therapeutics Inc. and is not intended for distribution outside Calderwood & Harkness LLP without the prior written consent of Ian Blackwood.
Right-click to update Table of Contents
I. Executive Summary
Calderwood & Harkness LLP ("C&H") has been retained by Genome Dx Therapeutics Inc. ("GenomeDx" or "GDT"), a clinical-stage biotechnology company headquartered at 450 Genome Way, Suite 300, South San Francisco, California 94080, to represent GenomeDx as borrower in connection with a proposed $15,000,000 senior secured bridge loan facility (the "Bridge Loan" or the "Facility"). This memorandum provides the engagement team with a comprehensive summary of the proposed transaction structure and identifies and analyzes the key negotiation points and risk issues for GenomeDx as borrower.
The purpose of the Bridge Loan is to fund GenomeDx's operations through the anticipated close of its Series C equity financing round (the "Series C"). GenomeDx's current cash runway, absent new capital, is estimated to extend only through the second quarter of 2026, making the bridge financing essential to the company's continued operations and the progression of its lead therapeutic candidate, GDT-2701, through Phase 2 clinical trials for frontotemporal dementia.
The lender syndicate consists of two participants: (i) Pinnacle Venture Lending Corp. ("Pinnacle"), a specialty venture lending platform, which is committing $10,000,000 (representing 66.67% of the aggregate commitments) and will act as Administrative Agent under the Facility; and (ii) Cobalt Life Sciences Fund III, L.P. ("Cobalt"), a healthcare-focused credit fund, which is committing $5,000,000 (representing 33.33% of the aggregate commitments) as a participating lender. Pacific Fiduciary Services Inc. ("PFS") has been engaged to serve as Collateral Agent.
The Lenders are represented by Hargrove, Finch & Calloway LLP ("HFC"), with the matter led by Catherine "Kate" Hargrove, Partner, and Jaylen Torres, Senior Associate.
With respect to the transaction timeline, the parties executed a term sheet on February 10, 2026. C&H is scheduled to circulate the first draft of the Bridge Loan Agreement to HFC on February 14, 2026. Signing is targeted for early March 2026, with funding expected to follow shortly thereafter. The Bridge Loan has a twelve-month maturity, with a Maturity Date of March 6, 2027.
The sections that follow provide a detailed overview of the transaction, including background on the borrower and lenders, the key commercial terms of the Facility, the proposed collateral and security package, the financial covenants, conditions precedent to funding, and warrant coverage and conversion mechanics. Part III of this memorandum identifies and analyzes the key negotiation points and risk issues that the team should focus on as we prepare the initial draft of the Bridge Loan Agreement. Part IV addresses additional structural and process considerations, and Part V sets forth our recommended next steps.
II. Transaction Overview
A. The Borrower — GenomeDx Background
GenomeDx is a Delaware corporation, qualified to do business in the State of California. The company's Employer Identification Number is 82-4917263, and its Delaware file number is 7481263. GenomeDx's registered agent in Delaware is National Registered Agents of Delaware Inc., located at 1209 Orange Street, Wilmington, Delaware 19801.
GenomeDx was founded in 2019 and is focused on the development of a proprietary RNA-based diagnostic and therapeutic platform targeting rare neurodegenerative diseases. The company's lead candidate, GDT-2701, is currently in Phase 2 clinical trials for frontotemporal dementia. GenomeDx's executive team and key board members are as follows:
• Chief Executive Officer: Dr. Ananya Mehta, PhD. Dr. Mehta is a co-founder of GenomeDx and a molecular biologist. She previously served as Chief Scientific Officer at Celanova Biosciences Inc.
• Chief Financial Officer: Robert "Rob" Langford, CPA. Mr. Langford previously served as Vice President, Finance at Helix Pathway Inc. He oversees all financial planning, treasury, and investor relations functions at GenomeDx.
• General Counsel: Miriam Sato. Ms. Sato is a former associate at Redstone Park LLP and serves as GenomeDx's in-house legal advisor. She will serve as the company's primary internal point of contact for the transaction.
• Lead Independent Director: Dr. Harold Voss, MD. Dr. Voss serves as the lead independent director on GenomeDx's board of directors and will be a key voice on governance matters arising from the bridge financing, including the dilutive impact of the warrant and conversion features.
GenomeDx's intellectual property portfolio consists of 14 issued United States patents and 7 pending Patent Cooperation Treaty (PCT) applications, all of which are assigned to GenomeDx. The patents and patent applications are currently subject to a negative pledge under GenomeDx's existing equipment financing facility with Ridgeline Capital Partners LLC ("Ridgeline"), which is discussed further below. The intellectual property portfolio is central to GenomeDx's value proposition and will constitute a significant component of the collateral package for the Bridge Loan.
GenomeDx completed its Series B equity financing round in August 2024, raising $42,000,000 at a price of $2.18 per share. The Series B round was led by Verdana Health Ventures Fund II, L.P. ("Verdana"), which currently holds approximately 24.6% of GenomeDx's equity on a fully diluted basis. Verdana maintains a board observer seat held by Julia Engström, Partner at Verdana. The relationship between GenomeDx and Verdana is relevant to the Bridge Loan transaction in several respects, including Pinnacle's existing lending relationships with three other Verdana portfolio companies and Verdana's non-binding indication of interest in co-leading the anticipated Series C round.
GenomeDx's current capitalization consists of approximately 48,500,000 shares outstanding on a fully diluted basis. Based on the Series B price of $2.18 per share, this implies a post-money valuation of approximately $105,730,000 (48,500,000 shares × $2.18 per share).
With respect to existing indebtedness, GenomeDx has $3,200,000 outstanding under an equipment financing facility with Ridgeline Capital Partners LLC, which matures in December 2027. Ridgeline holds a first-priority security interest in specifically identified equipment financed under that facility and related proceeds. As noted above, the Ridgeline facility also includes a negative pledge covering GenomeDx's entire patent portfolio, which is a matter that will need to be addressed in the context of the Bridge Loan collateral package and the intercreditor arrangement. We discuss this issue in detail in Section III.B below.
B. The Lenders
1. Pinnacle Venture Lending Corp.
Pinnacle Venture Lending Corp. is a Delaware corporation with its principal office at 2200 Sand Hill Road, Suite 400, Menlo Park, California 94025. Pinnacle is a specialty venture lending platform focused on providing debt financing to life sciences and technology companies, with approximately $2.8 billion in assets under management. The lead contact at Pinnacle for this transaction is Marcus Reinhardt, Managing Director, Life Sciences Lending. Pinnacle's internal deal reference number is PVLC-2026-LSL-0047.
Pinnacle is committing $10,000,000 to the Facility, representing 66.67% of the aggregate commitments of $15,000,000. Pinnacle will also serve as Administrative Agent under the Bridge Loan Agreement. Notably, Pinnacle has previously provided debt financing to three other portfolio companies of Verdana, GenomeDx's lead equity investor. This existing relationship likely facilitated GenomeDx's ability to secure favorable pricing for the Facility and suggests a degree of institutional familiarity between Pinnacle and GenomeDx's investor base.
2. Cobalt Life Sciences Fund III, L.P.
Cobalt Life Sciences Fund III, L.P. is a Delaware limited partnership whose general partner is Cobalt Capital Management III LLC. Cobalt's principal office is located at 600 Lexington Avenue, 22nd Floor, New York, New York 10022. Cobalt is a healthcare-focused credit fund with approximately $1.4 billion in assets under management. The key contact at Cobalt is Priya Anand, Partner.
Cobalt is committing $5,000,000 to the Facility, representing 33.33% of the aggregate commitments. Cobalt does not hold any equity in GenomeDx. Cobalt has an existing co-lending relationship with Pinnacle, having participated alongside Pinnacle in prior transactions, which facilitates alignment between the two lenders on key terms.
C. Facility Terms Summary
The principal commercial terms of the proposed Bridge Loan are summarized below. These terms reflect the executed term sheet dated February 10, 2026, as supplemented by subsequent discussions between the parties and their respective counsel.
Facility Type: Senior secured bridge loan structured as a single-draw term loan. The full $15,000,000 commitment is expected to be drawn in a single advance at closing.
Aggregate Commitment: $15,000,000. Pinnacle: $10,000,000 (66.67%). Cobalt: $5,000,000 (33.33%).
Interest Rate: 6.00% per annum (600 basis points), fixed. Interest is to be calculated on a 360-day-year / actual-days-elapsed basis, which is standard for commercial lending transactions. Based on the full commitment of $15,000,000, the annual interest cost is $900,000, or approximately $75,000 per month.
Interest Payment: Interest is payable monthly in arrears on the first business day of each calendar month, commencing April 1, 2026.
Default Rate: 8.00% per annum (the base rate of 600 basis points plus a 200 basis point default premium). The default rate applies automatically upon the occurrence and during the continuance of an Event of Default.
Maturity Date: March 6, 2027, which is twelve months from the anticipated signing date.
Governing Law: The Bridge Loan Agreement and related transaction documents will be governed by the laws of the State of California.
Voluntary Prepayment: GenomeDx may prepay the Bridge Loan at any time in whole or in part without premium or penalty, subject to providing five (5) business days' prior written notice to the Administrative Agent. The absence of a prepayment premium is a favorable term for GenomeDx.
Mandatory Prepayment: GenomeDx is required to apply 100% of net cash proceeds from any equity financing raising gross proceeds in excess of $20,000,000 to the repayment of the Bridge Loan in full, including all outstanding principal, accrued and unpaid interest, and any other amounts owing under the Facility. This provision is designed to capture the anticipated Series C proceeds and is discussed further in Section III.G below.
Commitment Fee: A commitment fee equal to 1.00% of the aggregate commitments, totaling $150,000 (Pinnacle: $100,000; Cobalt: $50,000), is payable at closing. This is a one-time, non-refundable fee.
Administrative Agent Fee: An annual administrative agent fee of $25,000 is payable to Pinnacle at closing and on each anniversary of the closing date.
Lenders' Counsel Fees: GenomeDx is responsible for the reasonable and documented fees and expenses of HFC, the Lenders' counsel, subject to a cap of $175,000 for the initial closing. This cap applies only to fees and expenses incurred through the initial closing; any post-closing advisory work or amendment-related work by HFC would be billed separately and would be subject to the "reasonable and documented" standard but would not be subject to the $175,000 cap.
Borrower's Counsel Fees: C&H's engagement-level budget estimate for the transaction is $210,000, billed on an hourly basis. This estimate is not a cap and may be revised as the transaction progresses, particularly if the intercreditor negotiations or other issues prove to be more complex than currently anticipated.
D. Collateral and Security Package
The Bridge Loan will be secured by a first-priority perfected security interest in substantially all assets of GenomeDx, including, but not limited to, intellectual property (patents, patent applications, trade secrets, and know-how), accounts receivable, equipment (subject to the intercreditor arrangement described below), deposit accounts, general intangibles, and instruments. The first-priority lien of the bridge lenders on the collateral is subject to the carve-out for assets over which Ridgeline holds a first-priority lien under the existing equipment financing facility, as will be set forth in the intercreditor agreement.
Collateral Agent: Pacific Fiduciary Services Inc. will serve as Collateral Agent for the Facility. The primary contact at PFS is David Nakamura, Vice President, Corporate Trust. PFS's office is located at 350 Mission Street, Suite 1200, San Francisco, California 94105. PFS will hold the security interest on behalf of the lender syndicate and will be responsible for administering the collateral arrangements, including maintaining the necessary filings and recordings.
UCC-1 Financing Statements: UCC-1 financing statements will be filed with the Delaware Secretary of State, as the jurisdiction of GenomeDx's incorporation, to perfect the security interest in personal property collateral under Article 9 of the Uniform Commercial Code. A protective UCC-1 filing will also be made with the California Secretary of State. The Delaware filing will be the primary perfection filing; the California filing is precautionary and addresses any residual risk that a filing in the state of the borrower's principal place of business could be required or beneficial.
IP Security Agreement: A separate short-form IP Security Agreement will be executed and recorded with the United States Patent and Trademark Office to perfect the security interest in GenomeDx's intellectual property portfolio, which covers the 14 issued U.S. patents and 7 pending PCT applications. This filing is necessary because, under federal law, a security interest in issued patents must be recorded with the USPTO to achieve perfection, and recording at the USPTO provides additional constructive notice to third parties.
Deposit Account Control Agreements: Deposit account control agreements ("DACAs") will be required for GenomeDx's operating account (account number ending in **7834) and payroll account (account number ending in **2091), both of which are maintained at First Basin National Bank. DACAs are necessary to perfect the security interest in deposit accounts under UCC § 9-104, as a financing statement alone is insufficient to perfect a security interest in deposit accounts. The DACAs will establish the lenders' control over these accounts, subject to customary "springing" control provisions that allow GenomeDx to continue to use the accounts in the ordinary course of business until an Event of Default occurs.
E. Financial Covenants
The Bridge Loan Agreement will include two financial covenants, as set forth below:
Minimum Cash Covenant: GenomeDx is required to maintain unrestricted cash and cash equivalents of not less than $3,000,000 at all times. This covenant will be tested monthly as of the last business day of each calendar month. A breach of this covenant would constitute an Event of Default under the Bridge Loan Agreement. The implications of this covenant for GenomeDx's cash runway are analyzed in detail in Section III.E below.
Maximum Capital Expenditure Covenant: GenomeDx's capital expenditures are not to exceed $2,500,000 in any trailing twelve-month period without the prior written consent of the Required Lenders. "Required Lenders" is defined as Lenders holding more than 50% of the aggregate commitments, which, given Pinnacle's 66.67% share, means Pinnacle alone constitutes the Required Lenders. The practical implications of this threshold are discussed in Section IV.E below.
F. Conditions Precedent to Funding
The obligation of the Lenders to fund the Bridge Loan at closing is subject to the satisfaction or waiver of the following ten conditions precedent:
1. Execution and Delivery of Transaction Documents. GenomeDx shall have executed and delivered (or caused to be executed and delivered) all transaction documents, including the Bridge Loan Agreement, the Security Agreement, the IP Security Agreement, the Warrant Agreements (one for each Lender), and the Intercreditor Agreement among Pinnacle (as Administrative Agent), Ridgeline, GenomeDx, and PFS (acknowledging).
2. Officer's Certificate. GenomeDx shall have delivered an officer's certificate, executed by an authorized officer, attaching (i) resolutions of the board of directors authorizing the transaction, (ii) a certified copy of GenomeDx's certificate of incorporation (as amended), (iii) GenomeDx's bylaws (as amended), and (iv) an incumbency certificate identifying the officers authorized to execute the transaction documents.
3. Good Standing Certificates. GenomeDx shall have delivered certificates of good standing (or equivalent) from the Delaware Secretary of State and the California Secretary of State, each dated within ten (10) days of the closing date.
4. Perfection Deliverables. All perfection deliverables shall have been completed or arranged for, including (i) filing of UCC-1 financing statements with the Delaware Secretary of State and the California Secretary of State, (ii) execution and delivery of DACAs with First Basin National Bank for accounts **7834 and **2091, and (iii) execution and recording of the short-form IP Security Agreement with the USPTO.
5. C&H Legal Opinion. C&H shall have delivered to the Lenders a legal opinion in customary form, covering matters including due authorization, execution, delivery, enforceability, no conflicts, and perfection of the security interest.
6. HFC Legal Opinion. HFC shall have delivered to the Lenders a legal opinion in customary form for the benefit of the Lenders (this is an internal deliverable of the Lenders and does not require GenomeDx's involvement, but GenomeDx's cooperation with HFC's due diligence may be required).
7. Insurance Certificates. GenomeDx shall have delivered certificates of insurance evidencing (i) directors and officers liability insurance maintained with Sentinel Specialty Insurance Co. with a policy limit of $10,000,000, and (ii) general commercial liability insurance maintained with Commonwealth Mutual Insurance Group with a policy limit of $5,000,000. The certificates must show that the policies are in full force and effect and must name the Administrative Agent and the Collateral Agent as additional insureds or loss payees, as applicable.
8. FY2025 Audited Financial Statements. GenomeDx shall have delivered its audited financial statements for the fiscal year ended December 31, 2025, prepared in accordance with generally accepted accounting principles (GAAP) and audited by Clearview & Associates LLP. The audit opinion, which is expected to be issued on February 14, 2026, will include a going-concern qualification, the implications of which are discussed in Section III.F below.
9. Payment of Fees. GenomeDx shall have paid (i) the commitment fee of $150,000 (Pinnacle: $100,000; Cobalt: $50,000) and (ii) the administrative agent fee of $25,000 to Pinnacle.
10. Lien Search Results. The Lenders shall have received lien search results (UCC, federal tax lien, judgment, and intellectual property searches) confirming that there are no liens or encumbrances on GenomeDx's assets other than Permitted Liens (which will be defined in the Bridge Loan Agreement to include the existing Ridgeline security interest in specifically identified equipment).
G. Warrant Coverage and Conversion Option
1. Warrant Coverage
As part of the consideration for the Bridge Loan, GenomeDx will issue common stock purchase warrants to each Lender with an aggregate value equal to 3.00% of each Lender's commitment amount. The warrant coverage is calculated as follows:
• Pinnacle: 3.00% × $10,000,000 = $300,000 in warrant value. At the Series B price of $2.18 per share, this equates to 137,614 warrant shares ($300,000 ÷ $2.18).
• Cobalt: 3.00% × $5,000,000 = $150,000 in warrant value. At the Series B price of $2.18 per share, this equates to 68,807 warrant shares ($150,000 ÷ $2.18).
• Total Warrant Shares: 206,421 shares.
The exercise price of the warrants will be the lesser of (a) $2.18 per share (the Series B price) and (b) 80% of the per-share price in the Series C Equity Financing. The warrants will have a term of ten (10) years from the date of issuance. The dilutive impact of the warrants and the implications of the exercise price ratchet are analyzed in Section III.D below.
2. Bridge-to-Series C Conversion Option
In addition to the warrant coverage, the Bridge Loan includes a conversion feature. If the Series C closes on or prior to the Maturity Date (March 6, 2027), the Lenders may elect to convert all or any portion of the outstanding principal of the Bridge Loan, plus accrued and unpaid interest, into shares of Series C preferred stock at a price per share equal to 80% of the Series C price per share (i.e., a 20% discount to the Series C price). This conversion option provides the Lenders with an equity upside mechanism and, if exercised, eliminates GenomeDx's cash repayment obligation to the extent of the converted amount. The dilutive impact of the conversion option and its interplay with the mandatory prepayment mechanics are analyzed in Sections III.C and III.G below.
H. Key Timeline
The following table sets forth the key dates and milestones for the transaction:
III. Key Negotiation Points and Risk Analysis
This section identifies and analyzes the principal negotiation points and risk issues arising from the proposed Bridge Loan structure. These issues should guide the engagement team's approach in preparing the first draft of the Bridge Loan Agreement and in anticipating the positions that HFC and the Lenders are likely to take in the negotiation process.
A. Interest Rate — Appropriateness of 600 bps
The proposed interest rate for the Bridge Loan is 6.00% per annum (600 basis points), fixed. Based on our review of comparable venture lending bridge facilities for clinical-stage life sciences companies, this rate is at or slightly below the midpoint of the prevailing market range, which typically falls between 550 and 850 basis points depending on a number of factors, including credit quality, collateral coverage, stage of clinical development, equity sponsor support, and overall market conditions at the time of pricing.
Several factors support the competitive pricing that GenomeDx has been able to obtain:
• Strong Lead Equity Sponsor. Verdana's position as lead equity investor, holding approximately 24.6% of GenomeDx's fully diluted equity, provides the Lenders with comfort regarding the quality of GenomeDx's investor base and the likelihood of a successful Series C round. Verdana's indication of interest in co-leading the Series C further reinforces this confidence.
• First-Priority Lien on Substantially All Assets. The bridge lenders will receive a first-priority security interest in substantially all of GenomeDx's assets, excluding only the specifically identified equipment subject to Ridgeline's first-priority lien. The breadth of the collateral package, including the valuable IP portfolio, reduces the lenders' risk and supports a lower coupon.
• Warrant and Conversion Sweeteners. The warrant coverage (3.00% of commitments) and the conversion option (20% discount to Series C price) provide the Lenders with equity upside that supplements the interest income from the loan. These features effectively reduce the lenders' required coupon, as they receive a blended return from interest income, warrant value, and the potential conversion discount.
• Pinnacle's Existing Relationships. Pinnacle has previously provided debt financing to three other Verdana portfolio companies, which suggests an established institutional relationship that likely facilitated preferential pricing and a more efficient diligence process.
From GenomeDx's perspective, the fixed rate provides certainty for cash planning purposes. Unlike a floating-rate facility tied to SOFR or another benchmark, the fixed rate eliminates interest rate risk and allows GenomeDx to project its monthly interest expense with precision. The annual interest cost of $900,000 ($75,000 per month) is manageable relative to GenomeDx's anticipated cash position following the funding of the Bridge Loan, although it does represent a meaningful recurring cash outlay for a clinical-stage company with a limited revenue base.
Recommendation: The 600 basis point rate is favorable for GenomeDx, and we do not recommend seeking to renegotiate the interest rate unless other structural terms become materially more burdensome during the negotiation process. Any attempt to reduce the coupon would likely result in the Lenders seeking increased warrant coverage or a deeper conversion discount, which could ultimately be more costly to GenomeDx's existing shareholders. The team should bear in mind that the true all-in cost of capital to GenomeDx includes not only the interest rate but also the warrant coverage and conversion discount, which represent additional equity cost of capital as discussed in Sections III.C and III.D below.
B. Intercreditor Arrangement with Ridgeline Capital Partners LLC
1. Background. GenomeDx has $3,200,000 outstanding under an equipment financing facility (the "Ridgeline Facility") with Ridgeline Capital Partners LLC ("Ridgeline"), which matures in December 2027. Ridgeline holds a first-priority security interest in specifically identified equipment financed under the Ridgeline Facility and the related proceeds of that equipment. In addition, the Ridgeline Facility includes a negative pledge that covers GenomeDx's entire patent portfolio, which restricts GenomeDx from granting liens on its intellectual property to other creditors without Ridgeline's consent.
The simultaneous existence of the Ridgeline Facility and the proposed Bridge Loan necessitates an intercreditor agreement to delineate the relative rights and priorities of the two lender groups with respect to the collateral.
2. Proposed Structure
The proposed intercreditor arrangement would take the form of an intercreditor agreement among Pinnacle (in its capacity as Administrative Agent for the bridge lenders), Ridgeline, and GenomeDx, with PFS acknowledging in its capacity as Collateral Agent. The agreement would establish a split-collateral priority framework, as follows:
• "Ridgeline Priority Collateral" — the specifically identified equipment financed under the Ridgeline Facility and the related proceeds of that equipment. Ridgeline would hold a first-priority security interest in the Ridgeline Priority Collateral, and the bridge lenders would hold a junior lien on such collateral.
• "Bridge Priority Collateral" — all other assets of GenomeDx, including intellectual property, accounts receivable, deposit accounts, general intangibles, and instruments. The bridge lenders would hold a first-priority security interest in the Bridge Priority Collateral, and Ridgeline would hold a junior lien on such collateral (to the extent Ridgeline has any lien rights on such assets under the Ridgeline Facility).
• Cross-lien subordination — each party would agree to subordinate its junior lien on the other party's priority collateral, with the proceeds from any enforcement action allocated first to the party with priority on the relevant collateral.
Ridgeline is represented by Whitfield & Pratt LLP, Boston, with Elena Marchetti, Partner, as the lead attorney. The intercreditor term sheet is anticipated to be agreed by February 24, 2026.
3. Analysis of Key Issues
The following issues are expected to be the primary points of negotiation in the intercreditor agreement:
(i) Definition of "Ridgeline Priority Collateral." The definition of Ridgeline Priority Collateral must be narrowly tailored to the specific equipment schedule under the existing Ridgeline Facility. We should resist any attempt by Ridgeline or Whitfield & Pratt to include after-acquired equipment within the definition, or to adopt an expansive definition of "proceeds" that could capture accounts receivable or other assets generated through the use of the equipment. The definition should be limited to the specific items of equipment identified on the existing equipment schedule and their direct proceeds (e.g., insurance proceeds or proceeds from the sale of the specific equipment items), and should not extend to revenue or income generated by the use of the equipment.
(ii) Standstill Provisions. We should seek to include a standstill provision requiring Ridgeline to refrain from exercising remedies against the Ridgeline Priority Collateral for a reasonable period (typically 120 to 180 days in comparable transactions) following the occurrence of an event of default under the Ridgeline Facility. The standstill period would give GenomeDx and the bridge lenders time to cure the default or effect an orderly workout, and would prevent a disruptive enforcement action by Ridgeline that could impair GenomeDx's operations and, by extension, the bridge lenders' collateral position.
(iii) Enforcement Waterfall. The intercreditor agreement must include clear mechanics for the allocation of proceeds in the event of an enforcement action, particularly with respect to "mixed collateral" — i.e., collateral that is not clearly within the exclusive domain of either lender's priority collateral. Proceeds from mixed collateral must be allocated first to the party with priority on the relevant category of collateral, with any surplus flowing to the other party. The agreement should also address the treatment of commingled proceeds in deposit accounts.
(iv) Negative Pledge on Patents. The existing Ridgeline Facility includes a negative pledge that covers GenomeDx's entire patent portfolio. This is a significant issue because the grant of the bridge lenders' security interest in the IP — which is central to the Bridge Loan's collateral package — could arguably constitute a breach of the negative pledge, thereby triggering an event of default under the Ridgeline Facility. We need to carefully review the language of the negative pledge provision in the Ridgeline Facility to determine whether the grant of the bridge lender lien would constitute a violation. If it would, we will need to obtain a consent or waiver from Ridgeline as part of the intercreditor agreement, or alternatively, include a specific carve-out in the intercreditor agreement that expressly permits the bridge lender lien on the IP notwithstanding the negative pledge.
(v) Carve-Out for IP Collateral. More broadly, the intercreditor agreement should expressly confirm that intellectual property is not included within the definition of Ridgeline Priority Collateral, and that the bridge lenders hold a first-priority security interest in GenomeDx's IP portfolio. This is essential because the IP portfolio — the 14 issued patents and 7 pending PCT applications — constitutes a substantial portion of GenomeDx's enterprise value and is the most significant component of the bridge lenders' collateral package. Any ambiguity regarding the priority of the bridge lenders' lien on the IP could undermine the security package and create risk for both GenomeDx and the bridge lenders.
Recommendation: Prioritize ensuring that the intercreditor agreement (i) expressly carves out IP from the definition of Ridgeline Priority Collateral, (ii) addresses the negative pledge issue by obtaining Ridgeline's consent or waiver, and (iii) includes a reasonable standstill period of at least 120 days. The team should obtain and carefully review a copy of the Ridgeline Facility agreement, including all schedules and amendments, at the earliest opportunity.
C. Conversion Option — Dilutive Impact on Existing Shareholders
1. Structure. If the Series C closes on or prior to March 6, 2027 (the Maturity Date), the Lenders may elect to convert all or any portion of the outstanding principal of the Bridge Loan, plus accrued and unpaid interest, into shares of Series C preferred stock at a price per share equal to 80% of the Series C price per share (i.e., at a 20% discount to the price paid by the Series C investors).
2. Scenario Analysis
To assess the dilutive impact of the conversion option, we have prepared the following illustrative analysis based on the following assumptions:
• Full $15,000,000 principal outstanding at the time of conversion.
• Interest accrues for approximately six (6) months, assuming the Series C closes in August 2026, resulting in approximately $450,000 in accrued interest.
• Total convertible amount: approximately $15,450,000.
• Indicative Series C pre-money valuation of $140,000,000, with a target raise of $60,000,000 to $75,000,000.
• Indicative Series C price per share: approximately $2.89 per share (based on a simplified calculation of $140,000,000 pre-money valuation ÷ approximately 48,500,000 fully diluted shares).
Based on these assumptions, the conversion price at a 20% discount to the indicative Series C price would be approximately $2.31 per share ($2.89 × 80%). The number of conversion shares would be approximately 6,688,312 shares ($15,450,000 ÷ $2.31).
In addition to the conversion shares, the Lenders will receive a total of 206,421 warrant shares, as described in Section II.G above.
The combined bridge-related dilution is therefore approximately 6,894,733 shares on top of the existing approximately 48,500,000 fully diluted shares, representing approximately 12.5% incremental dilution (calculated as 6,894,733 ÷ (48,500,000 + 6,894,733)), before taking into account any new money shares issued in the Series C itself.
3. Impact on Existing Shareholders and Board Considerations
Verdana currently holds approximately 24.6% of GenomeDx's fully diluted equity. If Verdana co-leads the Series C, its percentage ownership may be maintained or increased through its new investment, but the conversion discount creates "cheap shares" for the bridge lenders relative to the price paid by new Series C investors. This effectively reduces the per-share value available to new Series C investors and dilutes all existing shareholders who do not participate in the conversion.
Dr. Harold Voss, as lead independent director, and Julia Engström, as Verdana's board observer, should both be apprised of the full dilutive impact of the conversion feature, including the scenario analysis presented above. Verdana's non-binding indication of interest in co-leading the Series C at an indicative pre-money valuation of approximately $140,000,000 was delivered before the conversion discount was finalized at 20%. We should coordinate with Miriam Sato to confirm that Verdana is aware of and comfortable with the conversion discount, as Verdana's support for the Series C could be affected if it views the bridge conversion as excessively dilutive.
4. Recommendation. GenomeDx should consider negotiating a cap on the convertible amount — for example, limiting the conversion to outstanding principal only, excluding accrued interest — to reduce the dilutive impact. Alternatively, GenomeDx could propose a higher discount floor (e.g., a 15% discount rather than 20%) or a cap on the aggregate number of shares issuable upon conversion. However, the conversion option is a standard feature of bridge-to-equity financing structures in the venture context, and it may be difficult to remove or significantly modify the feature given the Lenders' leverage in the current negotiation. We note that the conversion feature also has a potential benefit for GenomeDx: if GenomeDx's cash position is constrained at the time of the Series C, the conversion eliminates or reduces GenomeDx's cash repayment obligation under the Bridge Loan, which could be critical if the company's operating cash is insufficient to repay the facility in full.
D. Warrant Coverage — Impact on Fully Diluted Capitalization
1. Overview. As described in Section II.G, the Lenders will receive common stock purchase warrants with a total value equal to 3.00% of each Lender's commitment amount, resulting in the issuance of 206,421 warrant shares in the aggregate (Pinnacle: 137,614 shares; Cobalt: 68,807 shares). The exercise price of the warrants is the lesser of (a) $2.18 per share (the Series B price) and (b) 80% of the per-share price in the Series C.
2. Dilutive Impact
The 206,421 warrant shares represent approximately 0.43% incremental dilution relative to GenomeDx's existing fully diluted capitalization of approximately 48,500,000 shares (calculated as 206,421 ÷ 48,500,000). This level of dilution is modest and falls within market norms for venture bridge transactions, where warrant coverage of 2% to 5% of commitment amounts is typical, generally resulting in 0.3% to 1.0% incremental dilution.
3. Exercise Price Ratchet
The warrant exercise price includes a ratchet feature: the exercise price is the lesser of the Series B price ($2.18) or 80% of the Series C price per share. This means that if the Series C is priced above $2.73 per share ($2.18 ÷ 0.80 = $2.725), the exercise price will default to $2.18, the Series B price. Given the indicative Series C pre-money valuation of $140,000,000, the expected Series C price per share is approximately $2.89, which exceeds $2.73. Accordingly, the effective exercise price for the warrants is likely to be $2.18 per share.
If, however, the Series C is priced below $2.73 per share — which could occur if the pre-money valuation is lower than expected due to adverse clinical trial results, market conditions, or other factors — the exercise price would ratchet down to 80% of the lower Series C price, further increasing the dilutive impact of the warrants.
4. Anti-Dilution and Transfer Provisions
The Warrant Agreements will include anti-dilution protections for the Lenders. From GenomeDx's perspective, broad-based weighted-average anti-dilution is strongly preferred over full-ratchet anti-dilution. A full-ratchet provision would reprice the warrants to the lowest price at which GenomeDx issues equity in a subsequent "down round," regardless of the size of the down-round issuance, which could result in a dramatic increase in the number of shares issuable upon exercise. By contrast, a broad-based weighted-average formula takes into account the relative size of the down-round issuance and provides a more measured adjustment that is less punitive to existing shareholders.
The Warrant Agreements may also include registration rights provisions, which would give the Lenders the right to require GenomeDx to register the warrant shares for public sale in the event that GenomeDx undertakes an initial public offering. These provisions should be reviewed carefully to ensure they are consistent with GenomeDx's existing investors' rights agreement and do not create conflicts with the registration rights of the Series B investors.
Recommendation: The 3.00% warrant coverage is within market norms, and the 0.43% incremental dilution is modest. Our primary focus in negotiating the Warrant Agreements should be to ensure that (i) the anti-dilution protection is limited to broad-based weighted-average and does not include full-ratchet provisions, (ii) the registration rights provisions are consistent with GenomeDx's existing investors' rights agreement, and (iii) GenomeDx retains a right of first refusal on any transfers of the warrants by the Lenders, to allow GenomeDx to control its cap table and prevent the warrants from being transferred to unfamiliar or potentially adverse holders.
E. Minimum Cash Covenant — Projected Cash Runway
1. Covenant Structure
The minimum cash covenant requires GenomeDx to maintain unrestricted cash and cash equivalents of not less than $3,000,000 at all times, tested monthly as of the last business day of each calendar month. A breach of this covenant would constitute an Event of Default under the Bridge Loan Agreement, potentially entitling the Lenders to accelerate the outstanding obligations and exercise remedies against the collateral.
2. Cash Runway Analysis
GenomeDx's cash runway is currently estimated to extend through Q2 2026 absent new capital. With the $15,000,000 in Bridge Loan proceeds, less estimated closing costs of approximately $350,000 to $375,000 (consisting of the $150,000 commitment fee, the $25,000 administrative agent fee, and estimated Lenders' counsel and Borrower's counsel fees), net funding to GenomeDx is approximately $14,625,000 to $14,650,000.
As a clinical-stage company with GDT-2701 in Phase 2 clinical trials, GenomeDx's monthly cash burn rate is estimated to be in the range of $2,500,000 to $3,500,000 per month, encompassing clinical trial expenses, personnel costs, research and development expenditures, and general and administrative overhead. These figures are estimates and should be confirmed with Rob Langford. At an illustrative monthly burn rate of $3,000,000 and net bridge proceeds of approximately $14,600,000, the bridge loan would extend GenomeDx's runway by approximately 4.9 months, but this figure must be considered in the context of GenomeDx's existing cash balance (which we need to confirm with Rob Langford).
3. Covenant Compliance Risk
The $3,000,000 minimum cash covenant creates an effective "cushion" that reduces the amount of bridge proceeds available for operations. If GenomeDx's total cash position (existing cash plus net bridge proceeds) is approximately $16,000,000 — a reasonable estimate pending confirmation — and the monthly burn rate is $3,000,000, the company would breach the $3,000,000 minimum cash covenant in approximately 4.3 months (approximately mid-July 2026), assuming a linear depletion of cash and no other sources of incoming cash.
This analysis highlights a meaningful risk: if the Series C does not close by August or September 2026 as targeted, GenomeDx could breach the minimum cash covenant before the Maturity Date, triggering an Event of Default. Even a modest delay in the Series C timeline — due to market conditions, investor hesitation related to the going-concern qualification, or adverse clinical trial results — could push the company into covenant non-compliance.
4. Recommendation. We recommend the following actions with respect to the minimum cash covenant:
(i) Obtain detailed cash projections. As a first priority, we should obtain detailed twelve-month cash flow projections from Rob Langford to model covenant compliance under various scenarios, including (a) a base case in which the Series C closes in August 2026 as targeted, (b) a delay scenario in which the Series C closes in November or December 2026, and (c) a stress case in which the Series C does not close before the Maturity Date.
(ii) Negotiate a lower threshold. Consider negotiating a lower minimum cash threshold of $2,000,000, which would provide GenomeDx with additional runway before triggering a covenant breach. A reduction from $3,000,000 to $2,000,000 would extend the expected compliance period by approximately one month at a $3,000,000 monthly burn rate.
(iii) Negotiate a cure period. Request the inclusion of a cure period — for example, fifteen (15) business days from the date on which GenomeDx first becomes aware of or should have become aware of the breach — during which GenomeDx could cure the default by raising additional equity capital from existing investors (such as Verdana) or from other sources. The cure right should expressly permit cure through an equity infusion.
(iv) Request quarterly testing. Consider requesting that the covenant be tested quarterly rather than monthly, to reduce the risk of a technical breach caused by short-term cash fluctuations (such as a large vendor payment that temporarily depresses the cash balance below the threshold before a subsequent receipt replenishes it).
We recognize that the Lenders and HFC may resist some or all of these proposals, as the minimum cash covenant is a key protective feature for the lender syndicate. However, the concerns outlined above are legitimate and warrant a good-faith effort to achieve a more borrower-friendly formulation.
F. Going-Concern Qualification in FY2025 Audit Opinion
1. Background. Clearview & Associates LLP (Sandra Cho, Audit Partner) is expected to issue the FY2025 audit opinion on February 14, 2026. Based on our preliminary discussions with Rob Langford and Miriam Sato, the audit opinion will be unqualified but will include a going-concern qualification (technically, an "emphasis-of-matter" paragraph regarding going concern), contingent on GenomeDx's ability to obtain additional financing to fund continued operations.
2. Significance for the Transaction
A going-concern note signals to creditors, investors, and counterparties that the auditors have identified conditions that raise substantial doubt about GenomeDx's ability to continue as a going concern. While a going-concern qualification is a common feature for clinical-stage biotechnology companies that have not yet achieved profitability and are dependent on external financing, it carries specific implications for this transaction:
(i) Validation of Strategic Necessity. The going-concern note validates the strategic necessity of the Bridge Loan by demonstrating that GenomeDx requires bridge financing to continue operations. This is consistent with the transaction narrative and should not surprise the Lenders.
(ii) Condition Precedent Compliance. The audited financial statements, including the going-concern note, will be delivered to the Lenders as a condition precedent to funding. The Lenders are aware of GenomeDx's cash position and have priced the Facility accordingly, incorporating the interest rate, warrant coverage, and conversion discount to reflect the elevated risk profile associated with a clinical-stage borrower. The going-concern note should not itself be a barrier to closing, provided it is consistent with the Lenders' expectations and does not reveal any previously undisclosed material adverse information.
(iii) MAC Representation. The representations and warranties in the Bridge Loan Agreement will typically include a "no material adverse change" (or "material adverse effect") representation with respect to the financial statements delivered to the Lenders. The going-concern qualification may need to be specifically carved out of any MAC representation — for example, through language confirming that the going-concern note, standing alone, does not constitute a material adverse change. Alternatively, the going-concern note should be specifically disclosed on the applicable disclosure schedule so that it is captured within the scope of disclosed exceptions to the MAC representation.
(iv) Legal Opinion. C&H's legal opinion will include an enforceability opinion, which provides that the Bridge Loan Agreement and related documents are legal, valid, and binding obligations of GenomeDx enforceable in accordance with their terms. The going-concern note is an accounting matter rather than a legal impediment to enforceability, and accordingly, it should not affect C&H's ability to deliver the enforceability opinion. C&H will not be required to opine on GenomeDx's financial condition or the accuracy of its financial statements.
(v) Series C Implications. The going-concern note may affect GenomeDx's ability to attract the anticipated Series C co-investor. We understand that discussions are ongoing with Argonaut BioCapital Partners ("Argonaut") regarding potential co-investment in the Series C alongside Verdana. While sophisticated healthcare-focused investors like Argonaut are accustomed to seeing going-concern qualifications in the financial statements of clinical-stage biotech companies, the note could nevertheless be a factor in Argonaut's due diligence and pricing discussions. We should coordinate with Miriam Sato and Dr. Mehta on messaging to ensure that the going-concern note is presented in the appropriate context — i.e., that it is a mechanical consequence of GenomeDx's pre-revenue status and limited cash runway, and that the Bridge Loan and anticipated Series C are expected to address the going-concern condition.
3. Recommendation. Ensure that the MAC representation in the Bridge Loan Agreement includes a specific carve-out for the going-concern qualification in the FY2025 audit opinion. Flag this matter for the team members drafting the disclosure schedules, so that the going-concern note is properly disclosed. Coordinate with Miriam Sato on messaging to Argonaut and other potential Series C investors.
G. Mandatory Prepayment Mechanics and Interplay with Series C Financing
1. Mandatory Prepayment Trigger
The Bridge Loan Agreement will require GenomeDx to apply 100% of the net cash proceeds from any equity financing raising gross proceeds in excess of $20,000,000 to the repayment of the Bridge Loan in full, including all outstanding principal, accrued and unpaid interest, and any other amounts owing under the Facility.
The anticipated Series C targets $60,000,000 to $75,000,000 in gross proceeds, which will clearly exceed the $20,000,000 threshold. Therefore, the mandatory prepayment obligation will be triggered upon the closing of the Series C, and GenomeDx will be required to repay the Bridge Loan in full from the Series C proceeds, unless the Lenders elect to exercise their conversion option in lieu of cash repayment.
2. Interplay with Conversion Option
The mandatory prepayment obligation and the Lenders' conversion option must be carefully coordinated in the Bridge Loan Agreement to ensure a clear and workable framework. Specifically, the following issues must be addressed:
(i) Conversion Election Deadline. The Lenders' deadline for electing to convert their Bridge Loan claims into Series C preferred stock must be set prior to, or simultaneously with, the mandatory prepayment trigger date. If the conversion election deadline falls after the mandatory prepayment date, there is a risk that GenomeDx would be required to repay the Bridge Loan in cash before the Lenders have had the opportunity to elect conversion, creating a timing mismatch. We should propose that the Lenders' conversion election be made no later than a specified number of business days (e.g., ten (10) business days) prior to the anticipated closing date of the Series C.
(ii) Partial Conversion and Partial Repayment. The Bridge Loan Agreement should contemplate the possibility that one or both Lenders may elect to convert only a portion of their outstanding principal and accrued interest, with the remainder to be repaid in cash. The mechanics for partial conversion should be clear, including the allocation of the cash repayment and conversion amounts between the two Lenders.
(iii) Series C Documentation. The Series C purchase agreement and related documents must contemplate the issuance of Series C preferred stock upon conversion of the Bridge Loan. This will require coordination between C&H (as GenomeDx's counsel for the Bridge Loan) and the counsel handling the Series C (which may or may not be C&H) to ensure that the conversion mechanics are properly reflected in both the Bridge Loan Agreement and the Series C documentation.
3. Timing Considerations
The Series C is targeted for Q3 2026, with a closing expected in August or September 2026. If the Series C closes at that time, the Bridge Loan will have been outstanding for approximately five to six months, with approximately $375,000 to $450,000 in accrued interest. The total repayment or conversion amount would be approximately $15,375,000 to $15,450,000.
4. Risk — Series C Does Not Close
If the Series C does not close before March 6, 2027 (the Maturity Date), the full $15,000,000 in principal plus approximately $900,000 in accrued interest (assuming twelve months of accrual at 6.00% per annum) will be due and payable in cash at maturity. Given GenomeDx's current cash position and projected burn rate, the company will almost certainly not have the liquidity to repay the Bridge Loan in full at maturity absent a successful equity financing. This is the fundamental credit risk of the transaction and reinforces the critical importance of the Series C timeline for both GenomeDx and the Lenders.
5. Drafting Considerations
$20,000,000 Threshold. We should ensure that the $20,000,000 gross proceeds threshold for mandatory prepayment is tested on a per-transaction basis, not on a cumulative or aggregate basis. If the threshold were applied on a cumulative basis, a series of smaller equity raises — such as an insider round to cure a cash shortfall or a small strategic investment — could be aggregated to exceed $20,000,000 and trigger mandatory prepayment, even though no single financing was intended to be a "Series C" event. A per-transaction threshold ensures that only a significant equity financing — such as the anticipated Series C — triggers the mandatory prepayment obligation.
Carve-Out for Small Equity Raises. GenomeDx should consider whether it needs a carve-out for equity raises below a certain size that are not the Series C. For example, if GenomeDx needs to raise $5,000,000 in an insider round from existing investors to cure a cash shortfall or maintain compliance with the minimum cash covenant, such a raise should not trigger mandatory prepayment. We should propose a carve-out for equity financings raising gross proceeds of $20,000,000 or less, or alternatively, a specific exemption for equity issuances to existing stockholders in connection with an emergency or bridge financing below a defined threshold.
6. Verdana Comfort Letter
Verdana has delivered a comfort letter (not a guarantee) to the Lenders expressing its intent to participate in the Series C. This comfort letter is not legally binding and does not create an enforceable obligation on the part of Verdana to invest in the Series C or to invest at any particular valuation or on any particular terms. However, the comfort letter provides some degree of comfort regarding the likelihood of the Series C and the quality of GenomeDx's equity investor base. The comfort letter was one of the factors that facilitated the Lenders' willingness to commit to the Bridge Loan on the proposed terms.
7. Recommendation.
(i) Clarify the conversion election mechanics and timing in the Bridge Loan Agreement, ensuring that the conversion election deadline precedes the mandatory prepayment trigger date.
(ii) Confirm that the $20,000,000 gross proceeds threshold is tested on a per-transaction basis, not on a cumulative basis.
(iii) Consider whether GenomeDx needs a carve-out for equity raises below $20,000,000 that are not the Series C, and if so, propose appropriate carve-out language.
(iv) Coordinate with the team handling the Series C documentation (once identified) to ensure that the conversion mechanics are properly reflected in the Series C purchase agreement.
IV. Additional Structural and Process Considerations
A. Deposit Account Control Agreements
DACAs are required at First Basin National Bank for GenomeDx's operating account (account number ending in **7834) and payroll account (account number ending in **2091). DACAs are necessary to perfect the Lenders' security interest in GenomeDx's deposit accounts under UCC § 9-104.
Based on our experience with similar transactions, DACAs are frequently the longest-lead closing deliverable. Banks often have internal review and approval processes for DACAs that can take several weeks, particularly if the bank's standard form DACA differs from the form required by the Lenders. In addition, some banks may require separate fee arrangements or indemnification provisions in connection with DACAs.
Recommendation: We recommend that Daniel Obi coordinate with Miriam Sato and First Basin National Bank to initiate the DACA negotiation process promptly. Early engagement with First Basin will reduce the risk that DACA delays become a critical-path issue for closing. Daniel should request First Basin's standard form DACA and circulate it to HFC for review as soon as possible. If First Basin's form is materially different from the Lenders' preferred form, we should attempt to resolve any differences early in the process.
B. UCC and IP Filings
UCC-1 financing statements will be filed with the Delaware Secretary of State (as the primary filing jurisdiction, based on GenomeDx's state of incorporation) and with the California Secretary of State (as a protective filing in GenomeDx's state of principal place of business). These filings should be prepared in advance of closing and held for filing upon execution of the Security Agreement.
A separate short-form IP Security Agreement will be prepared for recording with the United States Patent and Trademark Office, covering the 14 issued U.S. patents and 7 pending PCT applications. The short-form IP Security Agreement will be in a form suitable for recording with the USPTO and will reference the underlying Security Agreement.
Recommendation: We should confirm with GenomeDx's IP counsel or in-house team (Miriam Sato) that there are no existing assignments or security interests recorded at the USPTO other than those arising from, or consistent with, the Ridgeline negative pledge. If there are any prior USPTO recordings that could create a priority issue, we need to identify and address them before closing. Daniel should arrange for preliminary IP searches at the USPTO to confirm the current state of the record.
C. Insurance Deliverables
As a condition precedent to closing, GenomeDx must deliver certificates of insurance evidencing the following coverage:
• Directors and Officers Liability Insurance: Maintained with Sentinel Specialty Insurance Co., with a policy limit of $10,000,000.